Espoo, April 7th, 2025. Saide Genomics has signed commercial contracts with UK-based Nonacus and Finland-based Euformatics to supply consumables and bioinformatics to their Lithuania-based clinical laboratory. This partnership aims at building the highest-throughput private NGS laboratory in the Baltics.
Saide Genomics is a high-ambition laboratory for clinical diagnostics and research that aims to become a center of personalized medicine and research, where innovative solutions for science and life are implemented. Their testing services cover both germline and somatic testing and NGS sequencing equipment range from Illumina MiSeq to highest throughput NovaSeq X Plus. This setup allows both flexibility and cost-efficiency regardless of the sample volume or sequencing depth.
After an in-depth evaluation of content and performance, Nexome, an NGS solution from Nonacus for whole exome sequencing (WES) was selected for its quality of capture delivering the highest on-target rates of the kits tested The Euformatics team analyzed the output of multiple kits from different vendors sequenced by Saide and reported the results to Saide’s team to make an informed decision based on various quality metrics from the raw data and aligned data. This revealed important insight into the coverage of difficult-to-sequence regions in the genome.
Euformatics clinical bioinformatics suite, the Genomics Hub, was selected after a proper testing period during which the Saide’s geneticists and bioinformaticians had full access to the platform and were able to build and test their workflow for analyzing samples from raw data to clinical reports. The application scientist team from Euformatics worked closely with Saide’s team to optimize filtering strategies and automating the bioinformatics workflow for the selected clinical use cases.
Arunas Leipus, the CEO of Saide Genomics, comments: ”Both Euformatics and Nonacus were very supportive and patient on our path to expand our testing offering from NIPT to whole exome sequencing. We now have a very efficient and high-performing workflow from the wet lab side to all the way to clinical reporting for analysing patient samples. We are looking forward to a multi-year partnership with both Euformatics and Nonacus to build the highest quality NGS lab in the Baltics.”
Chris Sale, Co-Founder and Chief Strategy Officer at Nonacus continues: ”We were very impressed with the aspirations of Saide Genomics and the attention to detail shown by Saide’s team in their evaluation of different kit providers. We are of course delighted that, based on performance and enhanced clinical content, our Nexome panel was selected to deliver their Whole Exome Sequencing service. Our experience of working together with Euformatics to deliver a complete solution from sample to report was extremely positive.
Tommi Kaasalainen, CEO of Euformatics, concludes: “Saide Genomics has the infrastructure and team in place to build a powerhouse of clinical NGS sequencing in the Baltics. I met their team in the Precision Medicine Forum in Riga in 2023 and it was quickly clear that our tools could contribute to what they were planning to do. Our team worked closely with them to select the most suitable kit provider, Nonacus, with whom we already had previous experience and are configuring our tools currently to highlight the key features of their oncology kits.”
The commercial partnership between Saide Genomics, Euformatics and Nonacus begun in early 2025. The companies are moving forward with validation of the test after which the clinical operation will start to scale.
About Euformatics:
Euformatics is a Finnish software company that specializes in high-standard bioinformatics tools for genomic data interpretation. Since 2010, Euformatics has been helping medical doctors and molecular genetics laboratories provide better precision medicine for cancer and common or rare disease diagnostics. At present, our core solution is the Genomics Hub which includes a variant interpretation tool; for clinical analysis and reporting of patient NGS data and a quality control tool; for NGS data quality management.
To learn more, visit www.euformatics.com
About Saide Genomics:
Saide Genomics is a center for molecular diagnostics, genomics and research. Since 2023, the company has been providing personalized medical solutions and services for patients from Lithuania and foreign clinics. Our mission is to ensure the highest global standards in diagnostic testing and genomic services.
To learn more, visit www.saidegenomics.com
About Nonacus:
Nonacus is a leading genomics company based in Birmingham, UK, dedicated to developing innovative diagnostic solutions that have the potential to enhance patient care. Through cutting-edge technology and a commitment to excellence, Nonacus provides high-quality genomic products and services to healthcare providers and researchers worldwide.
To learn more, visit www.nonacus.com/
Press Relations:
Tommi Kaasalainen
Euformatics
tommi.kaasalainen@euformatics.com
